Business Wire

First-of-Its-Kind “Pathways to Dairy Net Zero” Initiative to Raise Climate Ambition for the Global Dairy Sector

26.7.2021 12:00:00 EEST | Business Wire | Press release

Share

A first-of-its-kind Pathways to Dairy Net Zero initiative is being developed to accelerate climate change action throughout the global dairy sector. Announced today at the United Nations (UN) Food Systems Pre-Summit, the climate effort will be unlike any other in agriculture in terms of size, breadth, and scope.

“The global dairy sector is creating this ground-breaking initiative to help speed climate action already underway, while continuing to provide livelihoods for a billion people and important nutrition for six billion people,” said Donald Moore, Executive Director at the Global Dairy Platform.

A multi-stakeholder group of organizations, including the global dairy sector and representatives from the scientific and research communities, are working together to develop methodologies, tools and pathways that work for every dairy system. Pathways to Dairy Net Zero will officially launch during the UN Food Systems Summit in September and aims to generate commitments at the UN Climate Change Conference, COP26, in November.

New research to guide the initiative

Research is underway to identify where positive climate change action is possible across all dairy production systems and regions throughout the world. The study is being conducted by the Global Research Alliance on Agricultural Greenhouse Gases (GRA), the UN Food and Agriculture Organisation, Scotland’s Rural College and the New Zealand Agricultural Greenhouse Gas Research Centre. Preliminary findings include:

  1. Positive change is possible across all dairy systems and regions. Although there is a wide variety of production systems globally, there are opportunities for all to reduce greenhouse gas emission (GHG) intensity.1
  2. Collaboration is needed to reduce dairy’s emissions. Many climate, poverty, and malnutrition challenges can be addressed through adoption of best practices in similar dairy systems.2
  3. Reducing methane may be key to fast results. Methane, a primary GHG produced by ruminant livestock, is short-lived. As a result, more reductions in methane would have a more immediate effect on warming.3
  4. Dairy already has the means to reduce a significant proportion of emissions. 4 Initial evidence suggests emissions can be reduced up to 40 percent in some systems by improving productivity and resource use efficiency.
  5. Defining terminologies and targets will focus efforts to achieve the best results. As indicated in the Intergovernmental Panel on Climate Change (IPCC) Special Report: Global Warming of 1.5°C, dairy’s carbon dioxide emissions need to strive to Net Zero, but its methane reduction can range from 24-47 percent, and its nitrous oxide reduction can be 26 percent.5

“Our initial analysis suggests that wider use of existing GHG mitigation technologies will make an important impact in reducing dairy’s emissions in the short term, while the development of new innovations takes place,” said Hayden Montgomery, Special Representative of GRA. “This initiative may ultimately act as a blueprint for other livestock sectors,” he added.

For more information about Pathways to Dairy Net Zero, visit: www.GlobalDairyPlatform.com/PathwaysToDairyNetZero.

You can register here for the UN Food Systems Pre-Summit affiliated session “Raising the climate ambition for the agriculture sector: An approach from dairy” on Monday, July 26, at 19:30 CEST.

References:

  1. Food and Agriculture Organization of the United Nations (FAO). 2010. Greenhouse Gas Emissions from the Dairy Sector: A Life Cycle Assessment. Available at: http://www.fao.org/3/k7930e/k7930e00.pdf [Accessed July 2021].
  2. Food and Agriculture Organization of the United Nations (FAO). 2019. Climate change and the global dairy cattle sector: The role of the dairy sector in a low‐carbon future. Available at: http://www.fao.org/3/CA2929EN/ca2929en.pdf [Accessed July 2021].
  3. UN Environment Programme. 2021. Global Methane Assessment: Benefits and Costs of Mitigating Methane Emissions. Available at: https://www.unep.org/resources/report/global-methane-assessment-benefits-and-costs-mitigating-methane-emissions [Accessed July 2021].
  4. Gerber PJ, Steinfeld H, Henderson B, et al. 2013. Tackling climate change through livestock – A global assessment of emissions and mitigation opportunities. Food and Agriculture Organization of the United Nations (FAO), Rome. Available at: http://www.fao.org/3/i3437e/i3437e.pdf [Accessed July 2021].
  5. The Intergovernmental Panel on Climate Change (IPCC). 2018. Global warming of 1.5°C. An IPCC Special Report on the impacts of global warming of 1.5°C above pre-industrial levels and related global greenhouse gas emission pathways, in the context of strengthening the global response to the threat of climate change, sustainable development, and efforts to eradicate poverty. Available at: https://www.ipcc.ch/site/assets/uploads/sites/2/2019/06/SR15_Full_Report_Low_Res.pdf [Accessed July 2021].

About Pathways to Dairy Net Zero

This is a vibrant, growing movement, the first of its kind in the world. It brings together dairy production systems of every size and type, as well as organizations throughout the dairy supply chain. Collaborators include Global Dairy Platform, International Dairy Federation, Sustainable Agriculture Initiative Platform, International Livestock Research Institute, Dairy Sustainability Framework and IFCN Dairy Research Network. The Global Research Alliance on Agricultural Greenhouse Gases is a knowledge partner.

www.GlobalDairyPlatform.com/PathwaysToDairyNetZero

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kevin Burkum, Director of Communications
+1 847-627-3387
Kevin.Burkum@GlobalDairyPlatform.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye